How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,331 results for

Immune Thrombocytopenic Purpura

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Immune thrombocytopenic purpura

Immune thrombocytopenic purpura Immune thrombocytopenia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Immune thrombocytopenia Last reviewed: February 2019 Last updated: March 2019 Summary Immune thrombocytopenia (ITP), also known as immune thrombocytopenic purpura, is defined as an autoimmune haematological disorder characterised by isolated thrombocytopenia in the absence of an identifiable cause. Typically found (...) immune thrombocytopenia (ITP) is a haematological disorder characterised by isolated thrombocytopenia (platelet count <100 × 10⁹/L [<100 × 10³/microlitre]) in the absence of an identifiable cause. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009 Mar 12;113(11):2386-93. http://bloodjournal.hematologylibrary.org/cgi/content/full

2018 BMJ Best Practice

2. Fostamatinib for chronic immune thrombocytopenic purpura

Fostamatinib for chronic immune thrombocytopenic purpura Fostamatinib for chronic immune thrombocytopenic purpura Fostamatinib for chronic immune thrombocytopenic purpura NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Fostamatinib for chronic immune thrombocytopenic purpura. Birmingham: NIHR Horizon Scanning (...) Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Idiopathic thrombocytopenic purpura (ITP) occurs when the immune system destroys platelets, which are cells in the blood that are necessary for normal blood clotting. Persons with the disease have too few platelets in the blood which causes bleeding. Adults tend to get a chronic (long-term) form of the disease. Fostamatinib is a new drug for the treatment of ITP that is given as a tablet. Some studies have suggested

2016 Health Technology Assessment (HTA) Database.

3. Inherited thrombotic thrombocytopenic purpura mimicking immune thrombocytopenic purpura during pregnancy: a case report (PubMed)

Inherited thrombotic thrombocytopenic purpura mimicking immune thrombocytopenic purpura during pregnancy: a case report Thrombotic thrombocytopenic purpura is a very rare hereditary blood deficiency disorder of ADAMTS13 (von Willebrand factor-cleaving protease) and a life-threatening thrombotic microangiopathy characterized by thrombocytopenia and microangiopathic hemolytic anemia. The deficiency in ADAMTS13 metalloprotease, which cleaves the von Willebrand factor, may be congenital or acquired (...) . The congenital form is caused by inherited mutations in the ADAMTS13 gene. The diagnosis is challenging due to the nonspecific signs and symptoms, as well as the rarity of the disease.We present an unusual case of a 20-year-old feoderm woman from northeast region of Brazil who manifested thrombocytopenia during her pregnancy which was believed to be immune thrombocytopenic purpura.Considering the importance of a differential diagnosis of thrombotic microangiopathic disorders, congenital thrombotic

Full Text available with Trip Pro

2018 Journal of medical case reports

4. Post-Partum Thrombotic Thrombocytopenic Purpura (TTP) in a Patient with known Idiopathic (Immune) Thrombocytopenic Purpura: a case report and review of the literature (PubMed)

Post-Partum Thrombotic Thrombocytopenic Purpura (TTP) in a Patient with known Idiopathic (Immune) Thrombocytopenic Purpura: a case report and review of the literature Incidences of immune thrombocytopenic purpura occur in 1 in every 1000-10,000 pregnancies accounting for 3% of all thrombocytopenic pregnancies. A pre-existing immune thrombocytopenic purpura is known to be a risk factor for developing thrombocytopenia during pregnancy. We present here the treatment regime and management (...) of a patient with known immune thrombocytopenic purpura who developed postpartum thrombotic thrombocytopenia with atypical response to traditional therapy. Pregnant women are more vulnerable to immune thrombocytopenic purpura or thrombotic thrombocytopenia. Pregnancy or postpartum thrombotic thrombocytopenia accounts for 10-25% of all thrombotic thrombocytopenia.This case report deals with the treatment regime and management of a patient with known immune thrombocytopenic purpura who developed postpartum

Full Text available with Trip Pro

2018 Journal of medical case reports

5. Caplacizumab (Cablivi) - thrombotic thrombocytopenic purpura (aTTP)

Caplacizumab (Cablivi) - thrombotic thrombocytopenic purpura (aTTP) 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 28 June 2018 EMA/490172/2018 Committee for Medicinal Products for Human Use (CHMP) Assessment report Cablivi (...) /490172/2018 Page 4/88 List of abbreviations Ab Antibody ADA anti-drug antibodies ADAMTS13 a disintegrin and metalloprotease with thrombospondin type 1 motif, member 13 AE adverse event ALT alanine aminotransferase aPTT activated partial thromboplastin time ATC Anatomical Therapeutic Chemical AST aspartate aminotransferase aTTP acquired thrombotic thrombocytopenic purpura AUC_D area under the curve dose corrected AUCSS area under the curve at steady state BED biologically effective dose CI confidence

2018 European Medicines Agency - EPARs

6. Purtscher's retinopathy as the presenting manifestation of immune thrombocytopenic purpura (PubMed)

Purtscher's retinopathy as the presenting manifestation of immune thrombocytopenic purpura To report the case of a 52-year-old man with Purtscher's retinopathy as the presenting manifestation of immune thrombocytopenic purpura (ITP).Treatment with corticosteroids led to the resolution of hematologic findings within 1 week, and normal visual acuity was achieved after 2 months with no additional treatment.This is the first reported association between Purtscher's retinopathy and ITP. Complement

Full Text available with Trip Pro

2017 American journal of ophthalmology case reports

7. Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura (PubMed)

Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura Although steroids are routinely used as an adjunct to plasma exchange (PEX) therapy in the treatment of immune-mediated thrombotic thrombocytopenic purpura (iTTP), limited data regarding their efficacy or effect on ADAMTS13 biomarkers are available. We report the results of a prospective, randomized study that compared the effectiveness of prednisone or cyclosporine

Full Text available with Trip Pro

2017 Blood advances Controlled trial quality: uncertain

8. Romiplostim (Nplate) - chronic immune (idiopathic) thrombocytopenic purpura (ITP)

Romiplostim (Nplate) - chronic immune (idiopathic) thrombocytopenic purpura (ITP) Published 11 February 2019 1 www.scottishmedicines.org.uk Product update SMC2126 romiplostim 125 micrograms, 250 micrograms, 500 micrograms powder for solution for injection (Nplate®) Amgen Ltd 11 January 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice (...) is summarised as follows: ADVICE: following an abbreviated submission romiplostim (Nplate®) is accepted for restricted use within NHSScotland. Indication under review: chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients one year of age and older who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) SMC restriction: to use in patients with severe symptomatic ITP or patients with a high risk of bleeding. Romiplostim has previously been accepted for restricted use

2019 Scottish Medicines Consortium

9. Comparison of Rituximab originator (MabThera) to biosimilar (Truxima) in patients with immune-mediated thrombotic thrombocytopenic purpura. (PubMed)

Comparison of Rituximab originator (MabThera) to biosimilar (Truxima) in patients with immune-mediated thrombotic thrombocytopenic purpura. Immune thrombotic thrombocytopenic purpura (iTTP) is an acute, multisystem thrombotic microangiopathy mediated by ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) autoantibodies. Immunosuppression with anti-CD20 therapy is the mainstay of treatment. MabThera's patent has now expired and biosimilars have been

2019 British journal of haematology

10. Fatigue and cognitive impairment in immune thrombocytopenic purpura remain stable over time: short report from a longitudinal study. (PubMed)

Fatigue and cognitive impairment in immune thrombocytopenic purpura remain stable over time: short report from a longitudinal study. Immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterised by low platelet counts and increased bleeding risk. In 2009, two cross-sectional studies determined that fatigue and cognitive impairment (CI) were common in ITP. Here, we report the results from a longitudinal study of 34 people with ITP. Fatigue severity remained unchanged over 7 years

2019 British journal of haematology

11. Utilizing a PLASMIC score-based approach in the management of suspected immune thrombotic thrombocytopenic purpura: a cost minimization analysis within the Harvard TMA Research Collaborative. (PubMed)

Utilizing a PLASMIC score-based approach in the management of suspected immune thrombotic thrombocytopenic purpura: a cost minimization analysis within the Harvard TMA Research Collaborative. The PLASMIC score is a recently described clinical scoring algorithm that rapidly assesses the probability of severe ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) deficiency among patients presenting with microangiopathic haemolytic anaemia. Using a large (...) multi-institutional cohort, we explored whether an approach utilizing the PLASMIC score to risk-stratify patients with suspected immune thrombotic thrombocytopenic purpura (iTTP) could lead to significant cost savings. Our consortium consists of institutions with an unrestricted approach to ADAMTS13 testing (Group A) and those that require pre-approval by the transfusion medicine service (Group B). Institutions in Group A tested more patients than those in Group B (P < 0·001) but did not identify

2019 British journal of haematology

12. Immune Thrombocytopenic Purpura in Pregnancy. (PubMed)

Immune Thrombocytopenic Purpura in Pregnancy. Immune thrombocytopenia purpura (ITP), an autoimmune disease characterized by destruction of platelets, is a hematological disorder that can present in both pregnant and nonpregnant patients. Although thrombocytopenia in pregnancy can be caused by more common pathologies such as gestational thrombocytopenia and preeclampsia, ITP can present initially during pregnancy, further complicating diagnosis. Management must be considerate of both

2019 Obstetrical & Gynecological Survey

13. Prognostic and Long-term Survival of Immune Thrombotic Thrombocytopenic Purpura in older patients. (PubMed)

Prognostic and Long-term Survival of Immune Thrombotic Thrombocytopenic Purpura in older patients. Background: Immune Thrombotic Thrombocytopenic Purpura (iTTP) is a potentially lethal auto-immune disease. Older age is associated with increased iTTP mortality. Yet, data are scarce regarding iTTP occurring among older patients and their short- and long-term mortalities. Objective: To assess clinical features and long-term impact of iTTP on mortality in older patients (>60 yo). Patients

2019 Blood

14. Eltrombopag (Revolade) for children with chronic immune thrombocytopenic purpura

Eltrombopag (Revolade) for children with chronic immune thrombocytopenic purpura Eltrombopag (Revolade) for children with chronic immune thrombocytopenic purpura Eltrombopag (Revolade) for children with chronic immune thrombocytopenic purpura NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Eltrombopag (Revolade (...) ) for children with chronic immune thrombocytopenic purpura. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2014 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Benzoates; Child; Hydrazines; Infants; Purpura, Thrombotic Thrombocytopenic; Pyrazoles Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Centre, School of Health&Population

2014 Health Technology Assessment (HTA) Database.

15. Prospective Psychometric Evaluation Study of a Patient-reported Outcomes (PRO) Instrument for Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP]

Prospective Psychometric Evaluation Study of a Patient-reported Outcomes (PRO) Instrument for Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP] Prospective Psychometric Evaluation Study of a Patient-reported Outcomes (PRO) Instrument for Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP] - Full Text View (...) - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Prospective Psychometric Evaluation Study of a Patient-reported Outcomes (PRO) Instrument for Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary

2018 Clinical Trials

16. Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay between genes and environmental triggers. (PubMed)

Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay between genes and environmental triggers. Although outstanding progress has been made in understanding the pathophysiology of thrombotic thrombocytopenic purpura (TTP), knowledge of the immunopathogenesis of the disease is only at an early stage. Anti-ADAMTS13 auto-antibodies were shown to block proteolysis of von Willebrand factor and/or induce ADAMTS13 clearance from the circulation. However, it still (...) . Future studies have to identify why these identified genetic risk factors are also frequently to be found in the healthy population although the incidence of immune-mediated thrombotic thrombocytopenic purpura (iTTP) is extremely low. Moreover, the development of recombinant ADAMTS13 opens a new therapeutic era in the field. Interactions of recombinant ADAMTS13 with the immune system of iTTP patients will require intensive investigation, especially for its potential immunogenicity. Better

Full Text available with Trip Pro

2018 Haematologica

17. Erasmus syndrome associated with an immune thrombocytopenic purpura. (PubMed)

Erasmus syndrome associated with an immune thrombocytopenic purpura. 29314277 2018 06 26 1468-3083 32 7 2018 Jul Journal of the European Academy of Dermatology and Venereology : JEADV J Eur Acad Dermatol Venereol Erasmus syndrome associated with an immune thrombocytopenic purpura. e261-e262 10.1111/jdv.14785 Fouchard M M Department of Dermatology, University Hospital, 29609, Brest, France. Pan Petesch B B Department of Hematology, University Hospital, 29609, Brest, France. Abasq-Thomas C C

2018 Journal of the European Academy of Dermatology and Venereology

18. Immune thrombocytopenic purpura presenting in a patient after renal transplant for diabetic nephropathy. (PubMed)

Immune thrombocytopenic purpura presenting in a patient after renal transplant for diabetic nephropathy. Immune thrombocytopenic purpura (ITP) is primarily characterized by immune-mediated destruction of platelets in circulation. Major treatment options range from careful observation, steroids, immunosuppressive medications, immunoglobulins to splenectomy. Interestingly and rarely, ITP has also been reported after solid organ transplantation in patients receiving immunosuppressive medications

Full Text available with Trip Pro

2018 BMC Nephrology

19. Multiple total hip arthroplasties in refractory immune thrombocytopenic purpura: A case report and literature review. (PubMed)

Multiple total hip arthroplasties in refractory immune thrombocytopenic purpura: A case report and literature review. Refractory immune thrombocytopenic purpura (RITP) manifests as low platelet count, with a high risk of hemorrhage, treatment difficulty, and high mortality. Total hip arthroplasty (THA) in RITP is rarely reported. This study aimed to evaluate multiple THAs or revision total hip arthroplasties (RTHAs) in RITP.The male patient with RITP was 54-year-old patient and hospitalized (...) ; Refractory immune thrombocytopenic purpura (RITP).A RITP patient with femoral neck fracture received 2 THAs and 1 RTHA. First THA indication was significant left dislocation of Garden III type. RTHA was performed following prosthetic loosening after left total hip arthroplasty. The second THA was prompted by non-healing of the old fracture, significant pain, and a low Harris score. Platelet count remained <20 × 10/L, and conventional drugs, splenectomy, and platelet transfusion had no effects. A large

Full Text available with Trip Pro

2018 Medicine

20. Increased Frequency of Immune Thrombocytopenic Purpura in Coeliac Disease and Vice Versa: A Prospective Observational Study (PubMed)

Increased Frequency of Immune Thrombocytopenic Purpura in Coeliac Disease and Vice Versa: A Prospective Observational Study Coeliac disease (CD) and immune thrombocytopenic purpura (ITP) are immune conditions, often associated with other immune disorders. In recent years, increasing attention has been directed towards the association between ITP and CD.To investigate the frequency of ITP in CD patients and vice versa and to assess the risk of their association.This was a prospective

Full Text available with Trip Pro

2018 Gastroenterology research and practice

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>